The holiday season approaches, so here's a quick look at the year that was for Indian Pharma, before we disappear into a haze of year-end festivities. It's a mixed bag (what year isn't?) including stuff that could influence the way things work in the years ahead. For convenience, I've divided up what I think are … Continue reading India #Pharma 2014 : A quick look back – Part One #quality
Tag: ranbaxy
India’s safety culture: an oxymoron?
The regularity with which some or the other Indian company is making news for taking short cuts has got to be alarming. First it was pharma company Ranbaxy, then Wockhardt. And now it is auto firm -General Motors' Indian factory. In each case, employees took short cuts to beat the system and ended up jeopardising … Continue reading India’s safety culture: an oxymoron?
Guest column : The Ranbaxy fraud has revived the “counterfeits” debate. It shouldn’t.
In a strongly-worded opinion column for The Indian Express on the Ranbaxy fraud published last week, Amir Attaran of the University of Ottawa rightly calls on the Indian government to do more to ensure that drugs produced in India are safe and effective. But Attaran is wrong is when he uses references to the fraud … Continue reading Guest column : The Ranbaxy fraud has revived the “counterfeits” debate. It shouldn’t.
The Ranbaxy effect : My op-ed in The Indian Express
This morning's Indian Express op-ed page carries my views on the impact of the Ranbaxy revelations on Indian generics. To read click here. Just to clarify, I had attributed numbers on US imports of bulk drugs and finished medicines that I have cited in the column to Fortune magazine. The attribution appears to have fallen … Continue reading The Ranbaxy effect : My op-ed in The Indian Express
It takes a village : What Ranbaxy’s Synriam tells us
Synriam, Ranbaxy's new anti-malarial drug combination, is the first new drug R&D project by an Indian generics company that's yielded a marketable drug. That's big in itself as various media reports have acknowledged. To me, its key value lies not so much in its "firstness." Its value is even greater as a case study - … Continue reading It takes a village : What Ranbaxy’s Synriam tells us
Generic or innovator, manufacturing still make-or-break
The pharmaceutical industry puts a heavy premium on innovation - the ability to come up with new drugs. Indeed this separates the boys from the men. Generic pharmaceuticals however are seen as similar to any other commodity manufacturing sector. However, in the last two years one generic and one innovator have been both done in … Continue reading Generic or innovator, manufacturing still make-or-break
Apothecurry 